无创伤性测定门静脉压力与肝血流二法联合应用研究肝硬化的价值

目的　为临床研究肝硬化提供有价值的手段。方法　采用99mTc -RBC测定 93例肝硬化患者肝血流 ,选择峰时 (Tmax) ,半廓清时 (T1/2 )、廓清率 (K值 )、肝血流 (LBF)等作为观察指标 ,与正常对照组比较 ;同时用99mTc-MIBI经直肠给药测定其中 5 4例患者门静脉压力 (PVP) ,以心 /肝 (H/L)比值作为分流指数。结果　肝硬化组Tmax、T1/2 、K及LBF分别为 1.2 6± 0 .99(93)min、5 .75± 3.38(93)min、0 .15 4± 0 .116 (93)及 0 .6 10± 0 .2 89(93)L/min ,除Tmax外 ,与对照组均有非常显著性差异 ;Child -A、B、C级各组之间 (除Tmax外 )也均有非常显著性差异或显著性差异 ;Child -A、B、C级各组H/L分别为 0 .49± 0 .18(2 1)、0 .6 9± 0 .16 (15 )、0 .91± 0 .2 1(18) ;PVP分别为 2 .2 2± 0 .5 7(2 1)kPa、2 .85± 0 .38(15 )kPa及 3.5 4± 0 .6 5 (18)kPa。而对照组的H/L及PVP分别为 0 .30± 0 .12 (16 )及 1.6 1± 0 .38(16 )kPa。Child -A、B、C级各组分别与对照组及各组之间比较 ,除Child -B与C级组PVP无显著性差异 (P >0 .0 5 )外 ,其余均有非常显著性差异 (P <0 .0 1)及显著性差异 (P <0 .0 5 )。结论　本法测定肝血流及门脉压力方便 ,无创伤 ,对分析病情 ,判断疗效 ,指导制订治疗方案 ,估计预后等均有较     

^99mTc—MIBI心肌断层显像潘生丁试验对缺血性心脏病诊断的评价

本文对４０例冠心病患者和３２例正常人在潘生丁药物负荷前、后进行＾９９ｍＴｃ－ＭＩＢＩ心肌断层显像的资料进行了分析。结合潘生丁药物负荷前、后的＾９９ｍＴｃ－ＭＩＢＩ心肌断层图像和靶心图可对冠心病心肌缺血或心肌梗塞的部位、范围及严重程度作出有意义的评价，并可观察左室腔的大小和室壁厚薄等情况。其诊断冠心病的灵敏性为９２．５％、特异性为８７．５％。本文发现早期冠心病负荷显像表现的缺血区在静息状态下显像大多     

Monitoring of biological responses of tumor cells after irradiation with99mTc-MIBI — Anin vitro study

Summary To explore the possibility to employ^99mTc-MIBI to monitor biological response of tumor cells after irradiation and to observe the relation between the radiation doses and the uptake levels of^99mTc-MIBI in tumor cells, the cells were irradiated with a single dose of 2 Gy, 10 Gy and 20 Gy respectively. The uptake of^99mTc-MIBI in each dosage group was determined before and 24, 48, 72 h after irradiation respectively. Apoptosis index (AI), plating efficiency (PE) of tumor cells was simultaneously determined. There was a positive correlation between uptake levels of^99mc-MIBI and AI(r = −0.91,P< 0.05). A negative correlation was noted between the uptake levels and PE (r = −0.86,P< 0.05). It is suggested that^99mTc-MIBI may be used as a tracer to monitor the change of viability state of tumor cells after being irradiated with different doses.     

Effects of miltefosine on membrane permeability and accumulation of [Tc]-hexakis-2-methoxyisobutyl isonitrile, 2-[F]fluoro-2-deoxy-d-glucose, daunorubucin and rhodamine123 in multidrug-resistant and sensitive cells

Miltefosine is a phospholipid analog that exhibits antineoplastic activity against breast cancer metastases, but its mechanism of action remains uncertain. The aim of this study was to investigate the transport mechanism for the removal of miltefosine and [99mTc]-hexakis-2-methoxyisobutyl isonitrile (99mTc-MIBI) from multidrug-resistant cells. The P-glycoprotein pump function, cell viability, and 99mTc-MIBI and 2-[18F]fluoro-2-deoxy-D-glucose (18FDG) uptakes were measured in NIH 3T3 (3T3) and NIH 3T3MDR1 G185 (3T3MDR1) mouse fibroblasts and human lymphoid B JY cells. Miltefosine treatment increased the permeability and fluidity of these tumor cells in a concentration-dependent manner. The multidrug-sensitive cells were 3-4 times more sensitive to miltefosine than the multidrug-resistant ones. The extent of 99mTc-MIBI accumulation in the P-glycoprotein-expressing cells increased in the presence of miltefosine, whereas the rhodamine123 and daunorubicin uptakes of the cells did not change significantly. In the 3T3MDR1 cells verapamil reinstated the rhodamine123 and daunorubicin accumulation, but not the 99mTc-MIBI uptake. Cyclosporin A reinstated the uptakes of 99mTc-MIBI, daunorubicin and rhodamine123 by the 3T3MDR1 cells. In a concentration-dependent manner miltefosine decreased the extents of 99mTc-MIBI, rhodamine123, daunorubicin and 18FDG accumulation in the JY and 3T3 cells. Our findings indicate a common transport mechanism for 99mTc-MIBI and miltefosine, which is distinct from that for rhodamine123 and daunorubicin in MDR cells.     

化疗增敏剂影响 P-糖蛋白依赖多药耐药性肿瘤细胞~(99)Tc~m-MIBI 摄取的实验研究(英文)

目的观察化疔增敏剂对多药耐药性(Multi-drug resistance,MDR)肿瘤细胞 P-糖蛋白(P-glycoprotein,P-gp)的影响及伴随~(99)Tc~m-MI-BI 摄取动力学的变化,以建立用~(99)Tc~m-MIBI 来评价化疗增敏剂效果的方法。方法 MDR 人乳腺癌细胞 MCF-7/Adr 37℃培养。(1)实验组和对照组细胞培养基中分别加入化疗增敏剂维拉帕米(10 μmol/L)和等体积培养液 DMEM。~(99)Tc~m-MIBI 与细胞共同孵育2 h 后收集细胞,测定放射性活度和 P-gp 表达水平。(2)维拉帕米(10 μmol/L)加入细胞培养基中,与细胞孵育若干时间后~(99)Tc~m-MIBI 加入细胞培养基中,与细胞一起培养2 h 后收集细胞。测定放射性活度和P-gp 表达水平。结果 (1)维拉帕米作用2h 后,细胞摄取~(99)Tc~m-MIBI 较对照组显著增加(t=2.33,P<0.05),但 P-gp 表达水平差异无显著性(P>0.05)。(2)肿瘤细胞摄取~(99)Tc~m-MIBI 随维拉帕米作用时间的延长而增加,各时间点 UR 差异有显著性(F=58.2,P<0.05),并且,VRP 作用时间在80 min 内时,肿瘤细胞摄取~(99)Tc~m-MIBI 与 P-gp 的表达水平无相关性(r=0.16,P>0.05),VRP 作用时间大于8 h时,肿瘤细胞摄取~(99)Tc~m-MIBI 与 P-gp 的表达水平呈负相关(r=-0.73,P<0.01)。结论化疗增敏剂能够影响 P-gp 过度表达所致 MDR 肿瘤细胞对~(99)Tc~m-MIBI 的摄取。     

Uptake of99mTc-tetrofosmin,99mTc-MIBI and201TI in malignant thymoma

99mTc-tetrofosmin, Thallium-201-chloride (201Tl) and 99mTc-MIBI imagings were performed in a patient with malignant thymoma. Tracer uptake in the primary tumor was demonstrated. The tumor-to-background ratios of planar and SPECT imagings were 1.60 and 1.98 for 99mTc-tetrofosmin, 1.12 and 2.09 for 201Tl, and 1.19 and 1.80 for 99mTc-MIBI, respectively. In another patient 99mTc-tetrofosmin and 201Tl imagings were performed. Not only the primary tumor but also the direct invasions and metastatic lesions (bone metastases) were clearly detected. The tumor-to-background ratios of planar and SPECT imagings were 2.31 and 2.78 for 99mTc-tetrofosmin and 2.45 and 3.58 for 201Tl, respectively. In 99mTc-tetrofosmin scintigraphy we acquired delayed images, and the tumor-to-background ratios of planar and SPECT delayed images were 1.20 and 1.86, the retention ratios were -1.11 and -0.92 and the retention indices were -48.1 and -33.1, respectively. Our preliminary results suggest that 99mTc-tetrofosmin is useful in detecting not only the primary tumor but also metastatic lesions from malignant thymoma.     

~（99m）Tc－MIBI心肌断层显像硝酸异山梨酯试验对心肌存活的评价

采用９９ｍ锝─甲氧基异丁基腈异（９９ｍＴｃ－ＭＩＢＩ）结合硝酸异山梨酯静脉滴注，对２９例心肌梗塞患者进行心肌断层显像。所有患者均进行静态心肌断层显像，然后静脉给予硝酸异山梨酯，达到标准后给予９９ｍＴｃ－ＭＩＢＩ，１．５ｈ后以与静态显像相同的条件采集和处理。结果显示，静态心肌显像有３８．３％的节段呈现为灌注异常区，给予硝酸异山梨酯后有３９％的节段心肌灌注得到改善。结果表明，硝酸异山梨酯静脉输入能明显改善９９ｍＴｃ－ＭＩＢＩ对心肌梗塞患者心肌存活的探测效果。     

~(99m)Tc-MIBI门控心肌舒张末期影像与非门控心肌影像检测老年冠心病人的比较

目的　评价 99m Tc- MIBI门控心肌舒张末期影像 (EDI)与非门控心肌影像 (NGI)对检测老年人冠心病的实际应用价值。方法　对 58例己确诊和可疑冠心病患者 (47例有冠脉造影 )进行了 99m Tc- MIBI门控心肌灌注断层显像 ,并比较了门控舒张末期影像 (EDI)与非门控心肌影像(NGI)检测冠心病的诊断效能和一致性。结果　 EDI和 NGI检测冠心病的灵敏度分别为 84.84% (2 8/ 33)和 72 .72 % (2 4 / 33)。 5例冠心病患者中有4例 NGI未检出异常而 EDI发现有缺血。 EDI特异性为 85.71 % (1 2 / 1 4 ) ,NGI为 78.57% (1 1 / 1 4 )。总共检测 2 90个节段中 ,NGI检出 50个节段有心肌缺血 ,EDI为 83个节段 (P<0 .0 5)。两种方法间检测心肌节段异常的一致性为 85.1 7% (2 4 7/ 2 90 )。 EDI显示出比 NGI能检出更多的心肌缺血。结论　 99m Tc- MIBI电路控制心肌灌注断层显像的 EDI是一种有临床实用价值的老年冠心病检测方法     

头颈部肿瘤蜘~(99)Tc-MIBI阳性显像的临床研究

目的探讨~(99m)Tc-MIBI亲肿瘤显像在头颈部肿瘤定性诊断中的应用价值。方法 91例临床初诊为头颈部肿瘤的患者和20例正常志愿者进行了早期和延迟的~(99m)Tc-MIBI头颈部断层显像。结果 ~(99m)Tc-MIBI早期／延迟显像诊断头颈部恶性肿瘤的总体灵敏度、特异性、准确性及阳性预测值分别为78.7％／72.3％、72.1％／ 88.4％、75.6％／80.0％和75.5％／87.2％；鼻咽癌、非霍奇金淋巴瘤显像效果优于上颌窦癌。~(99m)Tc-MIBI显像对于鼻咽癌复发／残留以及鼻腔非霍奇金淋巴瘤定性诊断价值明显优于CT和MRI检查。结论 ~(99m)Tc-MIBI亲肿瘤显像在头颈部肿瘤的定性诊断中有较好的应用前景,在判断肿瘤的范围、局部侵犯及发现颅底、颅内的转移灶等方面有独特的优势。     

^99mTc—MIBI提前显像在心肌梗塞诊断中的应用

目的：探讨99mTc-MIBI心肌显像能否成为急性心肌梗塞的快速诊断手段。资料和方法：选择临床确诊的心肌梗塞患者35例，于注射99mTc－MIBI后10min与60min以相同条件分别进行SPECT显像，并以相同条件分析处理图像，记录心肝肺的放射性计数率，比较两次显像结果的差异。结果；10min像阳性率31.2％，60min像为308％，符合率95.2％。有22个节段（4．8％）两次显像缺损程度有差异，以下后壁居多（13／22.59.1％）。图像质量以60min像为佳，心脏计数率随时间延长而降低，而心肝比、心肺比升高。结论：10min显像与60min显像在本组病例中具有很好的诊断一致性，至少可为急性心梗提前50min提供诊断，可望成为急性心梗的一种快速诊断手段。